You searched for: rosiglitasoonravi (Estniska - Engelska)

rosiglitasoonravi järgselt ei
following rosiglitazone treatment, there were no new safety concerns noted in children compared to adult patients with type 2 diabetes mellitus.

rosiglitasoonravi tavaline algannus on 4 mg ööpäevas.
rosiglitazone therapy is usually initiated at 4 mg/day.

kliinilistes uuringutes on premenopausaalsed naised saanud rosiglitasoonravi.
premenopausal women have received rosiglitazone during clinical studies.

muud kliinilistes uuringutes on rosiglitasoonravi saanud premenopausaalsed naised.
others premenopausal women have received rosiglitazone during clinical studies.

aneemia rosiglitasoonravi võib põhjustada annusega seotud hemoglobiinitaseme langust.
anaemia rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.

muud ettevaatusabinõud kliinilistes uuringutes on rosiglitasoonravi saanud premenopausaalsed naised.
other precautions premenopausal women have received rosiglitazone during clinical studies.

hematoloogiline kontroll rosiglitasoonravi võib põhjustada annusega seotud hemoglobiinitaseme langust.
haematological monitoring rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.

rosiglitasoonravi pikaajalist efektiivsust ei ole uuritud (vt lõik 5. 1).
the long-term benefits of therapy with rosiglitazone have not been demonstrated (see section 5.1).

premenopausis anovulatoorsed naised kliinilistes uuringutes on premenopausaalsed naised saanud rosiglitasoonravi.
premenopausal anovulatory women premenopausal women have received rosiglitazone during clinical studies.

rosiglitasoonravi järgselt ei täheldatud lastel uusi ohutusprobleeme võrreldes ii tüüpi diabeediga täiskasvanutega.
following rosiglitazone treatment, there were no new safety concerns noted in children compared to adult patients with type 2 diabetes mellitus.

seetõttu tuleb maksaensüümide aktiivsust kontrollida kõikidel patsientidel enne rosiglitasoonravi alustamist ja seejärel perioodiliselt vastavalt arsti otsusele.
therefore, liver enzymes should be checked prior to the initiation of therapy with rosiglitazone in all patients and periodically thereafter based on clinical judgement.

kui alat tase tõuseb rosiglitasoonravi ajal > 3x kõrgemale normivahemiku ülempiirist, tuleb seda võimalikult peatselt uuesti kontrollida.
if alt levels are increased to >3x upper limit of normal during rosiglitazone therapy, liver enzyme levels should be reassessed as soon as possible.

42 lühiajalise kliinilise uuringu ühendandmete retrospektiivne analüüs viitab sellele, et rosiglitasoonravi võib seostada müokardi isheemia juhtude suurenenud riskiga.
a retrospective analysis of data from 42 pooled short-term clinical studies indicated that treatment with rosiglitazone may be associated with an increased risk of myocardial ischaemic events.

arvestades südamepuudulikkuse võimalikku teket nendel patsientidel, ei tohi ägeda koronaarsündroomiga patsientidel rosiglitasoonravi alustada ning selle kasutamine tuleb ägeda faasi ajal katkestada (vt lõik 4.3).
in view of the potential for development of heart failure in these patients, rosiglitazone should therefore not be initiated in patients having an acute coronary event and it should be discontinued during the acute phase (see section 4.3).